Clobazam transdermal delivery system and uses thereof

A transdermal patch comprising:

• a. 10 to 90% w/w of microemulsion phase;
• b. 0.1% to 40% w/w of adhesive;
• c. 0.1 to 10% w/w of a crystallization inhibitor;
• d. a physiologically effective amount of clobazam loaded in the microemulsion phase, wherein the clobazam content of said patch remains substantially free of crystals when stored at 25° C. for at least four weeks;
• e. a backing layer;
• f. a drug-containing layer comprising the microemulsion phase, wherein the drug-containing layer is disposed on a body proximal side of the backing layer;
• and
• g. a body-contacting adhesive layer and a rate-control layer, wherein the body-contacting adhesive layer and the rate-control layer are disposed on a body proximal side of the drug-containing layer and reduce a flux rate of the clobazam, and wherein the body-contacting adhesive layer and the rate-control layer are made of a material that is different from the drug-containing layer.